Use: Labeled indications
- Dextrose (50%) Injection is indicated for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) in adults and pediatric patients 2 years of age and older.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Dextrose (50%) Injection is indicated for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) in adults and pediatric patients 2 years of age and older. Dextrose Injection (50%) is indicated for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) in adults and pediatric patients 2 years of age and older. (1)
Contraindications
4 CONTRAINDICATIONS Dextrose Injection (50%) is contraindicated in patients with: Intracranial or intraspinal hemorrhage because Dextrose Injection (50%) can worsen cerebral edema by causing a fluid shift across the blood-brain barrier. Severe dehydration because of the potential to worsen the patient’s hyperosmolar state.
Alcohol withdrawal because of the potential to precipitate Wernicke encephalopathy (WE) or cardiomyopathy in thiamine-deficient patients. Known hypersensitivity to dextrose [see Warnings and Precautions (5.2)]. Intracranial or intraspinal hemorrhage. (4) Severe dehydration. (4) Alcohol withdrawal. (4) Known hypersensitivity to dextrose.
(4)
US FDA labelDosing: Adult
- Only for intravenous infusion. Do not administer subcutaneously or intramuscularly. (2.1)
- Adults and Pediatric Patients 12 Years of Age and Older Administer into a central vein or large peripheral vein. Recommended dosage is 10 to 25 grams (20 to 50 mL) administered once. Repeated doses may be administered as clinically appropriate. (2.2)
- Pediatric Patients 2 to 11 Years of Age Administer into a central vein. Appropriate dosage depends on the age, weight, clinical and metabolic conditions of the patient, and concomitant therapy. (2.2)
- Maximum rate of dextrose administration without producing hyperglycemia is 0.5 g/kg of body weight/hour. (2.2)
- See full prescribing information for more information on preparation and administration instructions. (2.1, 2.2)
2.1 Important Preparation and Administration Instructions
2.1 Important Preparation and Administration Instructions Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use Dextrose Injection (50%) if the solution is cloudy or the seal has been broken. Obtain a blood glucose level prior to administering Dextrose Injection (50%).
However, in an emergency, administer Dextrose Injection (50%) promptly without awaiting blood glucose test results. Do not administer Dextrose Injection (50%) simultaneously with blood through the same infusion set because pseudoagglutination of red blood cells may occur. Administer Dextrose Injection (50%) intravenously.
Do not administer Dextrose Injection (50%) subcutaneously or intramuscularly. Discard the unused portion.
2.2 Recommended Dosage and Administration Adults and Pediatric Patients 12 Years of Age and…
2.2 Recommended Dosage and Administration Adults and Pediatric Patients 12 Years of Age and Older When possible, administer Dextrose Injection (50%) into a central vein or large peripheral vein because Dextrose Injection (50%) has an osmolarity greater than 900 mOsm/L and can cause venous irritation. The recommended dosage of Dextrose Injection (50%) is 10 to 25 grams (20 to 50 mL) of Dextrose Injection (50%), administered once via intravenous infusion.
Repeated doses may be administered as clinically appropriate. Slowly infuse Dextrose Injection (50%) to reduce the risk of developing hyperglycemia and to minimize venous irritation [see Warnings and Precautions (5.1, 5.3)]. The maximum rate at which Dextrose Injection (50%) can be infused without producing hyperglycemia is 0.5 g/kg of body weight/hour.
Pediatric Patients 2 to 11 Years of Age Administer Dextrose Injection (50%) into a central vein. Avoid administration of Dextrose Injection (50%) into a peripheral vein because Dextrose Injection (50%) has an osmolarity greater than 900 mOsm/L and can cause venous irritation [Warnings and Precautions (5.3)]. If central venous access cannot be obtained, consider using an alternative commercially available dextrose product with a lower concentration.
The appropriate dosage of Dextrose Injection (50%) depends on the age, weight, clinical and metabolic conditions of the patient, and concomitant therapy. Slowly infuse Dextrose Injection (50%) to reduce the risk of developing hyperglycemia and to minimize venous irritation [see Warnings and Precautions (5.1, 5.3)]. The maximum rate at which Dextrose Injection (50%) can be infused without producing hyperglycemia is 0.5 g/kg of body weight/hour.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Dextrose Injection (50%) is indicated in pediatric patients aged 2 years and older for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, or insulin shock). Monitor plasma electrolyte concentrations closely in pediatric patients who may have impaired ability to regulate fluids and electrolytes [see Warnings and Precautions (5.4)].
Pediatric patients treated with Dextrose Injection (50%) are at increased risk of developing hyponatremia and hyponatremic encephalopathy [see Warnings and Precautions (5.5)]. Dextrose Injection (50%) is not indicated for use in neonates. Dextrose Injection (50%) can increase the risk of developing hypo- or hyperglycemia in neonates, especially preterm neonates with low birth weight.
Excessive or rapid administration of Dextrose Injection (50%) may also result in increased serum osmolality and risk of intracerebral hemorrhage in very low birth weight neonates. Dextrose Injection (50%) is not indicated for use in pediatric patients younger than 2 years old due to the potential for excessive aluminum exposure.
If treatment with Dextrose Injection (50%) is necessary in a pediatric patient younger than 2 years old, use a different dextrose product [see Indications and Usage (1) and Warnings and Precautions (5.6)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Dextrose Injection (50%) has not been studied in a sufficient number of patients aged 65 and over to determine whether they respond differently from younger adult patients. Geriatric patients are at increased risk of developing hyponatremia and hyponatremic encephalopathy [see Warnings and Precautions (5.5)].
Other reported clinical experience has not identified differences in responses between the geriatric and younger adult patients. In general, the infusion rate for geriatric patients should start low and be titrated up cautiously, reflecting the greater risk for electrolyte abnormalities and fluid overload. Dextrose is known to be substantially excreted by the kidney, and the risk of adverse reactions to Dextrose Injection (50%) may be greater in patients with impaired renal function.
Because geriatric patients are more likely to have impaired renal function, care should be taken in selection of the infusion rate, and patients should be closely monitored during Dextrose Injection (50%) treatment.
Administration
2.1 Important Preparation and Administration Instructions Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use Dextrose Injection (50%) if the solution is cloudy or the seal has been broken. Obtain a blood glucose level prior to administering Dextrose Injection (50%). However, in an emergency, administer Dextrose Injection (50%) promptly without awaiting blood glucose test results. Do not administer Dextrose Injection (50%) simultaneously with blood through the same infusion set because pseudoagglutination of red blood cells may occur. Administer Dextrose Injection (50%) intravenously. Do not administer Dextrose Injection (50%) subcutaneously or intramuscularly. Discard the unused portion.
2.2 Recommended Dosage and Administration Adults and Pediatric Patients 12 Years of Age and Older When possible, administer Dextrose Injection (50%) into a central vein or large peripheral vein because Dextrose Injection (50%) has an osmolarity greater than 900 mOsm/L and can cause venous irritation. The recommended dosage of Dextrose Injection (50%) is 10 to 25 grams (20 to 50 mL) of Dextrose Injection (50%), administered once via intravenous infusion. Repeated doses may be administered as clinically appropriate. Slowly infuse Dextrose Injection (50%) to reduce the risk of developing hyperglycemia and to minimize venous irritation [see Warnings and Precautions (5.1 , 5.3) ] . The maximum rate at which Dextrose Injection (50%) can be infused without producing hyperglycemia is 0.5 g/kg of body weight/hour. Pediatric Patients 2 to 11 Years of Age Administer Dextrose Injection (50%) into a central vein. Avoid administration of Dextrose Injection (50%) into a peripheral vein because Dextrose Injection (50%) has an osmolarity greater than 900 mOsm/L and can cause venous irritation [ Warnings and Precautions (5.3) ] . If central venous access cannot be obtained, consider using an alternative commercially available dextrose product with a lower concentration. The appropriate dosage of Dextrose Injection (50%) depends on the age, weight, clinical and metabolic conditions of the patient, and concomitant therapy. Slowly infuse Dextrose Injection (50%) to reduce the risk of developing hyperglycemia and to minimize venous irritation [see Warnings and Precautions (5.1 , 5.3 )] . The maximum rate at which Dextrose Injection (50%) can be infused without producing hyperglycemia is 0.5 g/kg of body weight/hour.
US FDA labelDosage forms
Philippines
- Solution for iv infusion: 5 g/300 mg per 100 mL
- Solution for intravenous infusion: 5 g/300 mg per 100 mL
Registered products in the Philippines
8 products registered with the Food and Drug Administration (FDA) Philippines list Dextrose in 0 3 as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products8
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
A.N.B. Solution of Dextrose in Normal Saline5% Dextrose in 0.3% Sodium Chloride | Solution for Intravenous InfusionPolypropylene (PP) Plastic Bottles x 500 mL and 1000 mL Bottle of 1's | Rx | A.N.B. Laboratories Co., Ltd.Thailand | Optimum Trading | DR-XY35770 | May 4, 2031 | |
None5% Dextrose in 0.3% Sodium Chloride | 5 g/ 300 mg per 100 mL Solution for IV InfusionLDPE Plastic Bottle x 500 mL and 1000 mL | Rx | Albert David LimitedIndia | Medethix, Inc. | DRP-5055 | Jul 10, 2031 | |
None5% Dextrose in 0.3% Sodium Chloride | 5 g/300 mg per 100 mL Solution for Intravenous Infusion500 mL and 1 L PP Infusion Bottle w/ Butyl Rubber Stopper | Rx | Shanxi Nuocheng Pharmaceutical Co., Ltd.China | Endure Medical, Inc. | DR-XY39582 | Jun 8, 2031 | |
None5% Dextrose in 0.3% Sodium Chloride | Solution for Intravenous Infusion5-layer co-extrusion bag x 500mL n/a; 5-layer co-extrusion bag x 1000mL n/a | Rx | Shanxi Nuocheng Pharmaceutical Co., Ltd.China | Endure Medical Inc. | DR-XY41255 | Sep 19, 2027 | |
None5% Dextrose in 0.3% Sodium Chloride | Solution for IV InfusionUSP Type II Glass Bottle with rubber stopper and overseal x 500 mL & 1000 mL | Rx | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-658 | Oct 16, 2037 | |
None5% Dextrose in 0.3% Sodium Chloride | Solution for IV Infusion (see formulation at the back)Polypropylene Bag with Single Function Connector Cap x 500 mL and 1000 mL | Rx | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-XY46930 | Jun 30, 2030 | |
Unbranded5% Dextrose in 0.3% Sodium Chloride | 5 g/300 mg per 100 mL Solution for IV InfusionLDPE Plastic Bottle x 500 mL and 1000 mL Bot. of 1's | Rx | Albert David LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-5055-01 | Feb 6, 2032 | |
(no brand name)5% Dextrose in 0.3% Sodium Chloride | 5 g/ 300 mg per 100 mL Solution for IV Infusion500 mL and 1000 mL LDPE Bottle with white dust cap | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc | DRP-14313 | Aug 17, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 50% (25 g/50 mL) (500 mg/mL) of dextrose hydrous in a clear, colorless solution supplied as: Single-dose Ansyr ® II Plastic Syringe with syringe and barrel detached Single-dose Fliptop Vials Injection: 50% (25 g/50 mL) (500 mg/mL) of single-dose dextrose hydrous supplied as: Ansyr® II Plastic Syringe with syringe and barrel detached Fliptop Vials
Warnings/Precautions
- Hyperglycemia or Hyperosmolar Syndrome: Monitor blood and urine glucose; administer insulin as needed. (5.1)
- Hypersensitivity Reactions: Monitor for signs and symptoms and discontinue infusion immediately if reaction occurs. (5.2)
- Phlebitis and Thrombosis: Remove catheter as soon as possible if thrombophlebitis develops. (2.1, 5.3)
- Electrolyte Imbalance and Fluid Overload: Monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during administration. (5.4)
- Hyponatremia: Monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and neurologic status. (5.5)
- Potential Aluminum Toxicity for Patients with Immature or Impaired Renal Function: Prolonged administration of Dextrose Injection (50%) may lead to toxic levels of aluminum in pediatric patients with immature renal function or renal impairment, and in adults with renal impairment. (5.6)
5.1 Hyperglycemia and Hyperosmolar
5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State Significant hyperglycemia and hyperosmolar hyperglycemic state may result from too rapid administration of Dextrose Injection (50%). Symptoms of hyperosmolar hyperglycemic state include mental confusion and loss of consciousness. To minimize these risks, slowly infuse Dextrose Injection (50%) and monitor blood and urine glucose during treatment with Dextrose Injection (50%).
If Dextrose Injection (50%) is abruptly discontinued, patients should receive 5% or 10% dextrose injection to avoid rebound hypoglycemia.
5.2 Hypersensitivity Reactions
5.2 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have been reported with Dextrose Injection (50%) administration [see Adverse Reactions (6)]. Stop administration of Dextrose Injection (50%) immediately if signs or symptoms of a hypersensitivity reaction develop. Initiate appropriate treatment as clinically indicated.
5.3 Phlebitis and Thrombosis
5.3 Phlebitis and Thrombosis Dextrose Injection (50%) is hypertonic (has an osmolarity greater than 900 mOsm/L) and may cause phlebitis and thrombosis at the site of injection. If thrombophlebitis occurs, remove the catheter as soon as possible. Administer Dextrose Injection (50%) via slow intravenous infusion into a central vein (when possible) to reduce the risk of phlebitis and thrombosis.
Ensure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis occurs, stop administration of Dextrose Injection (50%) and initiate corrective measures.Avoid administration of Dextrose Injection (50%) into a peripheral vein in pediatric patients 2 to 11 years old. If central venous access cannot be obtained in these pediatric patients, consider using an alternative commercially available dextrose product with a lower concentration.
Do not administer Dextrose Injection (50%) subcutaneously or intramuscularly.
5.4 Electrolyte Imbalance and Fluid Overload
5.4 Electrolyte Imbalance and Fluid Overload Electrolyte deficits, particularly serum potassium and phosphate, may occur during prolonged use of Dextrose Injection (50%). Depending on the administered volume and the infusion rate, administration of Dextrose Injection (50%) can cause fluid overload including pulmonary edema.
Avoid Dextrose Injection (50%) in patients at risk for fluid and/or solute overload. If use cannot be avoided in these patients, monitor fluid balance, electrolyte concentrations, and acid base balance, especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration, and/or free water load.
5.5 Hyponatremia Dextrose
5.5 Hyponatremia Dextrose Injection (50%) may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy and vomiting. The risk of hospital-acquired hyponatremia is increased in pediatric patients, geriatric patients, patients treated with diuretics, and patients with cardiac or pulmonary failure or with the syndrome of inappropriate antidiuretic hormone (SIADH) (e.g., postoperative patients, patients concomitantly treated with arginine vasopressin analogs or certain antiepileptic, psychotropic, and cytotoxic drugs) [see Drug Interactions (7.1) and Use in Specific Populations (8.4)].
Avoid Dextrose Injection (50%) in patients with or at risk for hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations, chloride concentrations, fluid status, acid-base balance, and neurologic status [see Warnings and Precautions (5.4)].
5.6 Potential Aluminum Toxicity for Patients with Immature or Impaired Renal Function
5.6 Potential Aluminum Toxicity for Patients with Immature or Impaired Renal Function Dextrose Injection (50%) contains up to 600 mcg/L of aluminum. Prolonged administration of Dextrose Injection (50%) may lead to toxic levels of aluminum in pediatric patients with immature renal function. Due to the potential for excessive aluminum exposure, Dextrose Injection (50%) is not approved for pediatric patients younger than 2 years of age.
Parenteral aluminum exposure greater than 4 to 5 mcg/kg/day has been associated with central nervous system and bone toxicity in this age group. Prolonged administration of Dextrose Injection (50%) may also lead to toxic levels of aluminum in adults and pediatric patients with renal impairment.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Effects on Glycemic Control and Electrolyte Balance: Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations, and acid-base balance. Avoid use of Dextrose Injection in patients receiving drugs associated with hyponatremia. (7.1) 7.1 Drugs with Effects on Glycemic Control and Electrolyte Balance Dextrose Injection (50%) can affect glycemic control, vasopressin, and fluid and/or electrolyte balance [see Warnings and Precautions (5.1, 5.4, 5.5)].
Monitor patients’ blood glucose concentrations, fluid balance, serum electrolyte concentrations, and acid-base balance. Concomitant administration of Dextrose Injection (50%) with drugs associated with hyponatremia may increase the risk of developing hyponatremia. Drugs associated with hyponatremia include diuretics and those that cause SIADH (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), arginine vasopressin analogs, certain antiepileptic, psychotropic, and cytotoxic drugs).
Avoid use of Dextrose Injection (50%) in patients receiving drugs associated with hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations during concomitant use [see Warnings and Precautions (5.5)].
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are also described elsewhere in the labeling: Hyperglycemia and Hyperosmolar Syndrome [see Warnings and Precautions (5.1)] Hypersensitivity Reactions [see Warnings and Precautions (5.2)] Phlebitis and Thrombosis [see Warnings and Precautions (5.3)] Electrolyte Imbalance and Fluid Overload [see Warnings and Precautions (5.4)] Hyponatremia [see Warnings and Precautions (5.5)] The following adverse reactions associated with the use of Dextrose Injection were identified in clinical trials or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Administration site conditions: blister, extravasation, phlebitis, erythema, pain, vein damage, thrombosis Immune system disorders: anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritis, pyrexia, rash Cardiovascular disorders: cyanosis, volume overload The most common adverse reactions are hyperglycemia, hypersensitivity reactions, hyponatremia, infection (both systemic and at the injection site), vein thrombosis, phlebitis, and electrolyte imbalance. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Appropriate administration of Dextrose Injection (50%) during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. However, maternal hyperglycemia secondary to infusion of glucose-containing products at the time of delivery has been associated with adverse neonatal outcomes such as neonatal hypoglycemia.
Animal reproduction studies have not been conducted with dextrose. The background risk of major birth defects and miscarriage in patients with insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Mechanism of action
12.1 Mechanism of Action Dextrose restores blood glucose levels and provides a source of carbohydrate calories.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of dextrose have not been fully characterized.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Dextrose is oxidized to carbon dioxide and water.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as 5% Dextrose in 0.3% Sodium Chloride |
| PNF listing | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion) |
| PNF listing | Composition: Dextrose — 50 g/L Na+ — 51 mmol/L Cl- — 51 mmol/L |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Dextrose · ProPharma Distribution [US FDA-approved label, version 1, October 14, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5dceb1b4-e97a-a4fd-e063-6394a90a0392
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .